Cargando…

Genetic polymorphisms of PGF and TNFAIP2 genes related to cervical cancer risk among Uygur females from China

BACKGROUND: PGF and TNFAIP2 are important angiogenic factors, which were abnormal expression in cervical cancer (CC). However, there is currently no report investigating the relationship of PGF and TNFAIP2 gene polymorphisms to CC risk. METHODS: We conducted a case-control study of 342 CC patients a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ainiwaer, Zumurelaiti, Maisaidi, Reyilanmu, Liu, Jing, Han, Lili, Husaiyin, Sulaiya, Lu, Jing, Niyazi, Mayinuer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590450/
https://www.ncbi.nlm.nih.gov/pubmed/33109108
http://dx.doi.org/10.1186/s12881-020-01144-5
Descripción
Sumario:BACKGROUND: PGF and TNFAIP2 are important angiogenic factors, which were abnormal expression in cervical cancer (CC). However, there is currently no report investigating the relationship of PGF and TNFAIP2 gene polymorphisms to CC risk. METHODS: We conducted a case-control study of 342 CC patients and 498 cancer-free controls in a Chinese Uygur female population. Three SNPs (PGF rs8019391, PGF rs2268615, and TNFAIP2 rs710100) were selected and genotyped to assess the possible association of PGF and TNFAIP2 polymorphisms with CC susceptibility. Logistic regression analysis adjusted by age was used. RESULTS: PGF rs2268615 (OR = 1.39, 95% CI = 1.04–1.86, p = 0.024) and TNFAIP2 rs710100 (OR = 1.44, 95% CI =1.07–1.95, p = 0.018) polymorphisms were associated with the increased risk of CC. Moreover, T allele of PGF rs8019391 was highly represented in patients with stage III–IV compared with stage I-II (OR = 2.17, p = 4.58 × 10(− 4)). MDR analysis revealed a positive interaction between the SNPs. CONCLUSION: Our data indicated that PGF rs2268615, and TNFAIP2 rs710100 polymorphisms might be risk factors for CC susceptibility, which contributed to the increased risk of CC. TRIAL REGISTRATION: Not applicable. SUPPLEMENTARY INFORMATION: Supplementary information accompanies this paper at 10.1186/s12881-020-01144-5.